Jeffrey Leflein is a Rheumatology/Immunology physician affiliated with Ypsilanti District Library. OpenAlex indexes 36 publications with 1,046 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
83.8%Leukotriene Receptor Antagonist35.1%Montelukast Sodium100%Part D≥102 patientsCorticosteroid30.2%Symbicort41%Breo Ellipta18%Fluticasone Propionate15%Qvar Redihaler9%Pulmicort Flexhaler8%Dulera5%Flovent Hfa5%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
7.1%Corticosteroid7.1%Prednisone100%Part D≥45 patientsAnti-infectives
3.7%Macrolide Antimicrobial3.7%Azithromycin100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria
Journal of Allergy and Clinical Immunology
2026 - Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
Journal of Allergy and Clinical Immunology
2026 - 75573 Prolonged and Enhanced Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Barzolvolimab
Journal of the American Academy of Dermatology
2026 - VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age
Journal of Allergy and Clinical Immunology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”